JP2003531180A5 - - Google Patents

Download PDF

Info

Publication number
JP2003531180A5
JP2003531180A5 JP2001577990A JP2001577990A JP2003531180A5 JP 2003531180 A5 JP2003531180 A5 JP 2003531180A5 JP 2001577990 A JP2001577990 A JP 2001577990A JP 2001577990 A JP2001577990 A JP 2001577990A JP 2003531180 A5 JP2003531180 A5 JP 2003531180A5
Authority
JP
Japan
Prior art keywords
receptor agonist
composition according
ester
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001577990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531180A (ja
Filing date
Publication date
Priority claimed from US09/552,823 external-priority patent/US20030114482A1/en
Application filed filed Critical
Publication of JP2003531180A publication Critical patent/JP2003531180A/ja
Publication of JP2003531180A5 publication Critical patent/JP2003531180A5/ja
Pending legal-status Critical Current

Links

JP2001577990A 2000-04-20 2001-04-19 軟骨および骨の疾患の治療におけるレチノイド受容体拮抗薬または作用薬の使用 Pending JP2003531180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US09/552,823 2000-04-20
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (2)

Publication Number Publication Date
JP2003531180A JP2003531180A (ja) 2003-10-21
JP2003531180A5 true JP2003531180A5 (https=) 2008-06-05

Family

ID=24206947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001577990A Pending JP2003531180A (ja) 2000-04-20 2001-04-19 軟骨および骨の疾患の治療におけるレチノイド受容体拮抗薬または作用薬の使用

Country Status (9)

Country Link
US (1) US20030114482A1 (https=)
EP (1) EP1274456B1 (https=)
JP (1) JP2003531180A (https=)
AT (1) ATE285794T1 (https=)
AU (3) AU5548801A (https=)
CA (1) CA2407021A1 (https=)
DE (1) DE60108094T2 (https=)
HK (1) HK1053053B (https=)
WO (1) WO2001080894A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004019685D1 (de) * 2003-12-26 2009-04-09 Allergan Inc DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドx受容体関連化合物を用いた骨粗鬆症の治療剤
CA2667091C (en) * 2005-12-13 2014-06-10 Mcgill University Method for correcting a lipid imbalance in a subject
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
EP4066826B1 (en) 2010-09-01 2024-03-06 Thomas Jefferson University Retinoic acid receptor gamma agonists for muscle repair and regeneration
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
CA2890424C (en) 2012-11-08 2020-11-17 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
RS58045B1 (sr) 2013-05-22 2019-02-28 Univ Yamaguchi Inhibitor za retinohoroidalne poremećaje
SG11201810658PA (en) 2016-06-08 2018-12-28 Clementia Pharmaceuticals Inc Methods for treating heterotopic ossification
MX379489B (es) 2016-11-16 2025-03-11 Clementia Pharmaceuticals Inc Metodos para tratar la osteocondromatosis multiple (mo).
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
KR100485642B1 (ko) * 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
US20030125252A1 (en) * 2000-03-14 2003-07-03 Underhill T. Michael Compositions and methods for affecting osteogenesis

Similar Documents

Publication Publication Date Title
JP2003531180A5 (https=)
BR0101456A (pt) Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimento
SG153830A1 (en) Galenic formulations of organic compounds
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
YU92501A (sh) Levodop/karbidop/entakapon farmaceutski preparat
IL151791A (en) Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
NZ522326A (en) Adenosine A2A receptor antagonists
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
RU2005124363A (ru) Твердые пероральные дозируемые формы валсартана
EP0284612A1 (en) TREATMENT OF OSTEOPOROSIS.
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
BR0316908A (pt) Preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação
EP1399151A4 (en) METHOD FOR TREATING INFLAMMABLE DISEASES BY ADMINISTRATING A PPAR DELTA AGONIST
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
MXPA02012683A (es) Composiciones farmaceuticas solidas de valsartan.
TW200603816A (en) Risedronate compositions and their methods of use
JP2002525330A5 (https=)
MXPA02011524A (es) Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona.
EP1655026B1 (en) Solid pharmaceutical formulations comprising diacereine and meloxicam
JP2002537232A5 (https=)
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
RU97120700A (ru) Новое фармакологическое применение антагонистов a-ii рецептора
JP2005501108A5 (https=)